Patents Assigned to Therachon SAS
  • Soluble fibroblast growth factor receptor 3 (SFGFR3) polypeptides and uses thereof
    Patent number: 10294289
    Abstract: The invention features soluble fibroblast growth factor receptor 3 (sFGFR3) polypeptides. The invention also features methods of using sFGFR3 polypeptides to treat skeletal growth retardation disorders, such as achondroplasia.
    Type: Grant
    Filed: April 2, 2018
    Date of Patent: May 21, 2019
    Assignees: Therachon SAS, INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), UNIVERSITE NICE SOPHIA ANTIPOLIS
    Inventors: Elvire Gouze, Stéphanie Garcia